IP Library Granted Patent US 6,976,950
Granted Patent B2
US 6,976,950 · App. 10/391,446 · Granted Dec 20, 2005

Implantable valved pressure attenuation device

Assignee: Solace Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,976,950
App. No.
10/391,446
Granted
Dec 20, 2005
Kind
B2
Abstract

Disclosed herein are devices for treating symptoms of a urinary tract dysfunction having an expanded volume within the range of from about 1 cc to about 400 cc. In one embodiment, the device comprises a valve having a first membrane and a second membrane with a flow passage therebetween for filling the attenuation device. In another embodiment, the device comprises a valve for permitting the filling of the attenuation device through a filling device.

Claims (12)

1. A device for treating symptoms of a urinary tract dysfunction, comprising a compressible attenuation device having an expanded volume within the range of from about 1 cc to about 400 cc, and a valve for permitting filling of the attenuation device through a filling device; wherein the valve has a first pair of complementary surfaces for resisting deflation of the attenuation device, and a second pair of complementary surfaces for resisting additional filling of the attenuation device when the attenuation device is exposed to an external pressure which is greater than an internal pressure within the attenuation device.

2. A device for treating symptoms of a urinary tract dysfunction as in claim 1 , which is compressible to no more than about 80% of its expanded volume under a pressure of about 80 cm H 2 O.

3. A device for treating symptoms of a urinary tract dysfunction as in claim 1 , wherein the first pair of complementary surfaces are opposing surfaces on a flapper valve.

4. A device for treating symptoms of a urinary tract dysfunction as in claim 3 , wherein the flapper valve is oriented such that an increase in the internal pressure increases the closing pressure on the flapper valve.

5. A device for treating symptoms of a urinary tract dysfunction as in claim 4 , wherein the flapper valve extends into a chamber within the attenuation device.

6. A device for treating symptoms of a urinary tract dysfunction as in claim 1 , wherein closing pressure on the second pair of complementary surfaces is increased in response to an increase in pressure in the external environment surrounding the attenuation device.

7. A device for treating symptoms of a urinary tract dysfunction, comprising a compressible attenuation device having an expanded volume within the range of from about 1 cc to about 400 cc, and a valve having a first complementary surface and a second complementary surface with a flow passage therebetween for filling the attenuation device, wherein the first complementary surface is biased in the direction of the second complementary surface to close the valve when pressure external to the attenuation device is greater than pressure within the attenuation device, and the second complementary surface is biased in the direction of the first complementary surface to close the valve when pressure within the attenuation device exceeds pressure external to the attenuation device.

8. A device for treating symptoms of a urinary tract dysfunction as in claim 7 , wherein the first complementary surface is disposed in between the flow passage and the outside of the attenuation device.

9. A device for treating symptoms of a urinary tract dysfunction as in claim 7 , wherein the second complementary surface is disposed in between the flow passage and the inside of the attenuation device.

10. A device for treating symptoms of a urinary tract dysfunction as in claim 7 , wherein the flow path extends within a wall of the attenuation device, between a first opening into the attenuation device and a second opening to the outside of the attenuation device.

11. A device for treating symptoms of a urinary tract dysfunction as in claim 7 , wherein the flow path is normally collapsed under neutral pressure conditions.

12. A device for treating symptoms of a urinary tract dysfunction as in claim 7 , which is compressible to no more than about 80% of its expanded volume under a pressure of about 80 cm H 2 O.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2019
From: ATTENUEX TECHNOLOGIES, INC.
To: SOLACE THERAPEUTICS, INC.
Reel/Frame 049282/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2007
From: SOLACE THERAPEUTICS INC.
To: ATTENUEX TECHNOLOGIES, INC.
Reel/Frame 019407/0731 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2003
From: CONNORS, KEVIN G.; PINTAURO, WILLIAM L., M.D.; WALLIN, SHEILA K.; KILCOYNE, JOHN T.; CAO, HUNG H.; NGUYEN, KHOI M.; YUREK, MATTHEW T.
To: SOLACE THERAPEUTICS, INC.
Reel/Frame 013912/0296 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2003
From: CONNORS, KEVIN G.; PINTAURO, WILLIAM L.; WALLIN, SHEILA K.; CAO, HUNG H.; NGUYEN, KHOI M.; YUREK, MATTHEW T.
To: SOLACE THERAPEUTICS, INC.
Reel/Frame 013890/0776 →
Continuity (4)
Continuation In Part 0972330900 · Nov 27, 2000
Provisional Application 6019709500 · Apr 14, 2000
Provisional Application 6041594900 · Oct 3, 2002
Related Publication 20030236442A1 · Dec 25, 2003